Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239946 | 0.85 | CA1 (0.67) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL2519000 | 0.83 | CA1 (0.56) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL29681372 | 0.83 | CA1 (0.56) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL24554689 | 0.83 | CA1 (0.56) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL6661458 | 0.83 | CA1 (0.56) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL4549626 | 0.82 | CA1 (0.54) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL24136470 | 0.82 | CA1 (0.58) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7882663 | 0.79 | CA1 (0.51) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL6076887 | 0.76 | CA1 (0.48) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL25377331 | 0.76 | MEN1 (0.43) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2540720-B1 | 1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE DERIVATIVE AND USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | IMPDH1, IMPA1, DPYD | CA1 4719/4885CA2 3599/4885CA7 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.